Investor relations
All regulatory and non-regulatory releases from Medicortex International AB (publ).
Medicortex International AB (publ) (NGM: MEDFIN) develops non-invasive tests for traumatic brain injury (TBI) and concussion, based on biomarkers in urine and saliva. The company’s lead product candidate, ProbTBI™, is a hand-held,…
Settlement of a loan, a fee for expanding the shareholder base, and a consultancy receivable through newly issued shares Medicortex International AB (publ) (“Medicortex” or “the Company”) announces today that the Company has entered into…
Inga jämförelsetal finns för koncernen Koncernen uppstod genom det omvända förvärvet av Medicortex Finland Oyj den 29 juni 2026 och existerade inte under 2025 – jämförelsesiffror saknas därför helt. Periodens resultat innehåller dessutom…
No comparative figures available for the group. The Group came into existence through the reverse acquisition of Medicortex Finland Oyj on 29 June 2026 and did not exist during 2025 — comparative figures are therefore entirely unavailable.…
Medicortex International AB (publ) ("Medicortex" eller "Bolaget") meddelar att publiceringen av delårsrapporten för det andra kvartalet 2026 (april–juni), som enligt Bolagets finansiella kalender var planerad till idag den 28 augusti 2026,…
Medicortex International AB (publ) ("Medicortex" or "the Company") announces that the publication of the interim report for the second quarter of 2026 (April–June), which according to the Company’s financial calendar was scheduled for…
Letter from the Chairman to the Shareholders Dear Shareholders, The past year has marked a fundamental transformation for Medicortex. Following the reverse acquisition of Medicortex Finland Oyj, the change of name to Medicortex…
Dear Shareholders, I hope you have all had a wonderful summer. It has been a busy summer. On 30 June we completed the reverse takeover of Medicortex Finland Oyj, meeting all of NGM's conditions. The listed company – formerly NOSIUM AB…
Interim and annual reports, including attachments.
Get releases and reports by email as soon as they are published.
